OrbiMed's Isaly Interview on Drugmakers

Loading player, please wait...

Recommended Videos

  • Info

  • Comments

May 4 (Bloomberg) -- Samuel Isaly, a managing partner at OrbiMed Advisors LLC, talks with Bloomberg's Erik Schatzker about the first-quarter earnings of Merck & Co. and Pfizer Inc. and the outlook for consolidation among drugmakers. Merck said net income fell 79 percent to $298.8 million, or 9 cents a share, on charges related to its purchase of Schering-Plough. Pfizer's profit excluding certain items was 60 cents a share, beating analyst estimates. OrbiMed owns shares of both companies. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change